/ /

Ophthalmology

Phase IV study shows improved DME outcomes with fluocinolone acetonide implantThe fluocinolone acetonide 0.2 mcg/day implant (Iluvien, Alimera Sciences) offers an additional option for treating diabetic macular edema that reduces the need for subsequent therapy with anti-vascular endothelial growth factor or steroid treatment.
Basic estate planning protects individual and legacy
Integrating new technology into busy ophthalmic ASCAdopting new technologies across multiple practices using a single ambulatory surgery center can be challenging. A systematic approach leverages technology champions, employs consistent communications, and provides administrative support to secure reimbursement.
Bascom Palmer takes top honors in Ophthalmology Times Best Programs SurveyAfter a seven-year hiatus, Ophthalmology Times resumed its Best Programs Survey this fall. While a few new names popped up on the list, Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, Miami, remained at the top of the Best Overall Program category, followed again by the Wilmer Eye Institute at the Johns Hopkins University School of Medicine, Baltimore. Number three in the overall list has a new name with Dean McGee Eye Institute at the University of Oklahoma, Oklahoma City—the first time that institute has appeared in the top category since the survey’s inception 20 years ago.
Glaucoma 360 annual meeting will celebrate, innovate, educate in 2018
Fillers 101: Foundations for successThe foundations for success in using fillers during oculofacial surgery include understanding the characteristics of these products, which influences outcomes, and learning techniques to avoid and treat complications.
Cataract meeting outgrows Naples, moves to Amelia Island in 2018
Facial shaping with fillers an ‘artform’
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Techniques for lacrimal canalicular lacerations steadily improving